NO336551B1 - Forbedret ELISA for kalprotektin i fekalprøve eller gastrointestinaltraktsprøve - Google Patents

Forbedret ELISA for kalprotektin i fekalprøve eller gastrointestinaltraktsprøve

Info

Publication number: NO336551B1
Authority: NO; Norway
Prior art keywords: calprotectin; enzyme; sample; elisa; elisa according
Prior art date: 2011-06-21

Application number

NO20110896A

Other languages

English (en)

Norwegian (no)

Other versions

NO20110896A1 (no

Inventor

Magne Fagerhol

Original Assignee

Magne Fagerhol

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-06-21

Filing date

2011-06-21

Publication date

2015-09-28

2011-06-21 Application filed by Magne Fagerhol filed Critical Magne Fagerhol

2011-06-21 Priority to NO20110896A priority Critical patent/NO336551B1/no

2012-06-21 Priority to PCT/EP2012/061948 priority patent/WO2012175602A2/fr

2012-12-24 Publication of NO20110896A1 publication Critical patent/NO20110896A1/no

2015-09-28 Publication of NO336551B1 publication Critical patent/NO336551B1/no

Links

102000001109 Leukocyte L1 Antigen Complex Human genes 0.000 title claims description 78
108010069316 Leukocyte L1 Antigen Complex Proteins 0.000 title claims description 78
238000002965 ELISA Methods 0.000 title claims description 39
210000001035 gastrointestinal tract Anatomy 0.000 title claims description 8
238000012360 testing method Methods 0.000 title description 14
102000004190 Enzymes Human genes 0.000 claims description 24
108090000790 Enzymes Proteins 0.000 claims description 24
238000000034 method Methods 0.000 claims description 21
108010052500 Calgranulin A Proteins 0.000 claims description 17
102100032442 Protein S100-A8 Human genes 0.000 claims description 17
239000007787 solid Substances 0.000 claims description 17
239000007979 citrate buffer Substances 0.000 claims description 13
239000000872 buffer Substances 0.000 claims description 12
102100029812 Protein S100-A12 Human genes 0.000 claims description 9
108700016890 S100A12 Proteins 0.000 claims description 9
101150097337 S100A12 gene Proteins 0.000 claims description 9
239000000758 substrate Substances 0.000 claims description 8
108010052495 Calgranulin B Proteins 0.000 claims description 7
102100032420 Protein S100-A9 Human genes 0.000 claims description 7
238000003556 assay Methods 0.000 claims description 7
238000001514 detection method Methods 0.000 claims description 7
238000005406 washing Methods 0.000 claims description 7
102000002260 Alkaline Phosphatase Human genes 0.000 claims description 6
108020004774 Alkaline Phosphatase Proteins 0.000 claims description 6
239000002245 particle Substances 0.000 claims description 5
108010001336 Horseradish Peroxidase Proteins 0.000 claims description 4
238000011002 quantification Methods 0.000 claims description 4
102100031126 6-phosphogluconolactonase Human genes 0.000 claims description 2
108010029731 6-phosphogluconolactonase Proteins 0.000 claims description 2
108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 claims description 2
108010005774 beta-Galactosidase Proteins 0.000 claims description 2
230000029918 bioluminescence Effects 0.000 claims description 2
238000005415 bioluminescence Methods 0.000 claims description 2
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 2
239000010931 gold Substances 0.000 claims description 2
229910052737 gold Inorganic materials 0.000 claims description 2
239000006249 magnetic particle Substances 0.000 claims description 2
FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 claims 1
102000005936 beta-Galactosidase Human genes 0.000 claims 1
238000011534 incubation Methods 0.000 claims 1
238000002360 preparation method Methods 0.000 claims 1
239000000523 sample Substances 0.000 description 24
239000000284 extract Substances 0.000 description 21
229940088598 enzyme Drugs 0.000 description 19
108090000623 proteins and genes Proteins 0.000 description 16
102000004169 proteins and genes Human genes 0.000 description 14
239000011248 coating agent Substances 0.000 description 12
238000000576 coating method Methods 0.000 description 12
238000003018 immunoassay Methods 0.000 description 9
239000000427 antigen Substances 0.000 description 8
102000036639 antigens Human genes 0.000 description 8
108091007433 antigens Proteins 0.000 description 8
241000283973 Oryctolagus cuniculus Species 0.000 description 7
208000022559 Inflammatory bowel disease Diseases 0.000 description 6
108090000765 processed proteins & peptides Proteins 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
230000004054 inflammatory process Effects 0.000 description 5
206010061218 Inflammation Diseases 0.000 description 4
125000003275 alpha amino acid group Chemical group 0.000 description 4
230000027455 binding Effects 0.000 description 4
210000004027 cell Anatomy 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
238000000605 extraction Methods 0.000 description 4
239000003550 marker Substances 0.000 description 4
239000000047 product Substances 0.000 description 4
239000000243 solution Substances 0.000 description 4
108010032595 Antibody Binding Sites Proteins 0.000 description 3
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
102000005701 Calcium-Binding Proteins Human genes 0.000 description 3
108010045403 Calcium-Binding Proteins Proteins 0.000 description 3
229920001213 Polysorbate 20 Polymers 0.000 description 3
239000011324 bead Substances 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
229940098773 bovine serum albumin Drugs 0.000 description 3
239000011575 calcium Substances 0.000 description 3
229910052791 calcium Inorganic materials 0.000 description 3
230000021615 conjugation Effects 0.000 description 3
201000010099 disease Diseases 0.000 description 3
239000011536 extraction buffer Substances 0.000 description 3
238000005227 gel permeation chromatography Methods 0.000 description 3
230000014509 gene expression Effects 0.000 description 3
230000002209 hydrophobic effect Effects 0.000 description 3
210000000440 neutrophil Anatomy 0.000 description 3
239000002953 phosphate buffered saline Substances 0.000 description 3
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
239000012898 sample dilution Substances 0.000 description 3
239000000126 substance Substances 0.000 description 3
230000004572 zinc-binding Effects 0.000 description 3
238000012286 ELISA Assay Methods 0.000 description 2
101100476483 Homo sapiens S100A9 gene Proteins 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
241001529936 Murinae Species 0.000 description 2
108091028043 Nucleic acid sequence Proteins 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
239000000853 adhesive Substances 0.000 description 2
230000001070 adhesive effect Effects 0.000 description 2
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
229910052921 ammonium sulfate Inorganic materials 0.000 description 2
239000001166 ammonium sulphate Substances 0.000 description 2
235000011130 ammonium sulphate Nutrition 0.000 description 2
239000012491 analyte Substances 0.000 description 2
238000010171 animal model Methods 0.000 description 2
210000001124 body fluid Anatomy 0.000 description 2
239000010839 body fluid Substances 0.000 description 2
239000004202 carbamide Substances 0.000 description 2
230000005779 cell damage Effects 0.000 description 2
230000030833 cell death Effects 0.000 description 2
208000037887 cell injury Diseases 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
239000002738 chelating agent Substances 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000009833 condensation Methods 0.000 description 2
230000005494 condensation Effects 0.000 description 2
239000013078 crystal Substances 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
239000000539 dimer Substances 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
230000029142 excretion Effects 0.000 description 2
239000011888 foil Substances 0.000 description 2
238000002649 immunization Methods 0.000 description 2
230000003053 immunization Effects 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
210000001616 monocyte Anatomy 0.000 description 2
239000004033 plastic Substances 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
239000000376 reactant Substances 0.000 description 2
206010039073 rheumatoid arthritis Diseases 0.000 description 2
230000028327 secretion Effects 0.000 description 2
238000000926 separation method Methods 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000007790 solid phase Substances 0.000 description 2
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 2
229940033663 thimerosal Drugs 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
238000003260 vortexing Methods 0.000 description 2
239000011534 wash buffer Substances 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
108010092060 Acetate kinase Proteins 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
102000004145 Annexin A1 Human genes 0.000 description 1
108090000663 Annexin A1 Proteins 0.000 description 1
102100026189 Beta-galactosidase Human genes 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
201000003883 Cystic fibrosis Diseases 0.000 description 1
206010012289 Dementia Diseases 0.000 description 1
206010048768 Dermatosis Diseases 0.000 description 1
108090000331 Firefly luciferases Proteins 0.000 description 1
208000014540 Functional gastrointestinal disease Diseases 0.000 description 1
108010015776 Glucose oxidase Proteins 0.000 description 1
239000004366 Glucose oxidase Substances 0.000 description 1
108010029541 Laccase Proteins 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
241000288906 Primates Species 0.000 description 1
102000001253 Protein Kinase Human genes 0.000 description 1
108010052090 Renilla Luciferases Proteins 0.000 description 1
102000013674 S-100 Human genes 0.000 description 1
108700021018 S100 Proteins 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
238000002441 X-ray diffraction Methods 0.000 description 1
102100033220 Xanthine oxidase Human genes 0.000 description 1
108010093894 Xanthine oxidase Proteins 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
239000002250 absorbent Substances 0.000 description 1
230000002745 absorbent Effects 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
238000012870 ammonium sulfate precipitation Methods 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000000845 anti-microbial effect Effects 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000012620 biological material Substances 0.000 description 1
239000012472 biological sample Substances 0.000 description 1
239000000090 biomarker Substances 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
230000008859 change Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000010367 cloning Methods 0.000 description 1
230000037029 cross reaction Effects 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
239000012502 diagnostic product Substances 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
230000009266 disease activity Effects 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000013399 early diagnosis Methods 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000007515 enzymatic degradation Effects 0.000 description 1
230000002550 fecal effect Effects 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
210000003736 gastrointestinal content Anatomy 0.000 description 1
102000034356 gene-regulatory proteins Human genes 0.000 description 1
108091006104 gene-regulatory proteins Proteins 0.000 description 1
229940116332 glucose oxidase Drugs 0.000 description 1
235000019420 glucose oxidase Nutrition 0.000 description 1
230000035876 healing Effects 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
229940127121 immunoconjugate Drugs 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
239000004816 latex Substances 0.000 description 1
229920000126 latex Polymers 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000011344 liquid material Substances 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000000203 mixture Substances 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
229940126619 mouse monoclonal antibody Drugs 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
230000035772 mutation Effects 0.000 description 1
230000004770 neurodegeneration Effects 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
238000010606 normalization Methods 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
-1 pMactamase Proteins 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
230000004481 post-translational protein modification Effects 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
238000004393 prognosis Methods 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
210000003296 saliva Anatomy 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
238000012216 screening Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
230000011664 signaling Effects 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
239000011343 solid material Substances 0.000 description 1
230000007928 solubilization Effects 0.000 description 1
238000005063 solubilization Methods 0.000 description 1
238000004611 spectroscopical analysis Methods 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
239000011701 zinc Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4727—Calcium binding proteins, e.g. calmodulin

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Chemical & Material Sciences (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Food Science & Technology (AREA)
General Physics & Mathematics (AREA)
Cell Biology (AREA)
Biotechnology (AREA)
Medicinal Chemistry (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Microbiology (AREA)
Pathology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)
Investigating Or Analysing Biological Materials (AREA)
Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)

NO20110896A 2011-06-21 2011-06-21 Forbedret ELISA for kalprotektin i fekalprøve eller gastrointestinaltraktsprøve NO336551B1 (no)

Priority Applications (2)

Application Number	Priority Date	Filing Date	Title
NO20110896A NO336551B1 (no)	2011-06-21	2011-06-21	Forbedret ELISA for kalprotektin i fekalprøve eller gastrointestinaltraktsprøve
PCT/EP2012/061948 WO2012175602A2 (fr)	2011-06-21	2012-06-21	Quantification de la calprotectine par elisa

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
NO20110896A NO336551B1 (no)	2011-06-21	2011-06-21	Forbedret ELISA for kalprotektin i fekalprøve eller gastrointestinaltraktsprøve

Publications (2)

Publication Number	Publication Date
NO20110896A1 NO20110896A1 (no)	2012-12-24
NO336551B1 true NO336551B1 (no)	2015-09-28

Family

ID=46331308

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20110896A NO336551B1 (no)	2011-06-21	2011-06-21	Forbedret ELISA for kalprotektin i fekalprøve eller gastrointestinaltraktsprøve

Country Status (2)

Country	Link
NO (1)	NO336551B1 (fr)
WO (1)	WO2012175602A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2013132347A2 (fr) *	2012-03-06	2013-09-12	Calpro As	Immunodosage elisa amélioré de la calprotectine
WO2016116881A1 (fr) *	2015-01-23	2016-07-28	Westfälische Wilhelms-Universität Münster	Composés et procédés permettant la détection de la calprotectine
CN108290058B (zh)	2015-09-17	2023-05-16	美国安进公司	使用il23途径生物标志物预测il23拮抗剂的临床应答
US11220541B2 (en)	2015-12-22	2022-01-11	Amgen Inc.	CCL20 as a predictor of clinical response to IL23-antagonists
EP3487874A1 (fr)	2016-07-20	2019-05-29	Westfälische Wilhelms-Universität Münster	Standardisation spécifique d'un complexe de procédés immunologiques pour la quantification de s100a12
CN110609143A (zh) *	2019-10-31	2019-12-24	苏州普瑞森基因科技有限公司	一种钙卫蛋白异二聚体检测试剂盒及其应用
CN114891103B (zh) *	2022-06-11	2023-07-07	巴迪泰(青岛)生物科技有限公司	一种钙卫蛋白单克隆抗体及试剂盒
CN117607461A (zh) *	2023-12-06	2024-02-27	陕西省动物研究所	一种s100a8蛋白的检测方法及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU4790597A (en)	1996-11-01	1998-05-29	Nycomed Pharma As	Process for the extraction of proteins
EP1390058A2 (fr) *	2001-04-30	2004-02-25	Switch Biotech Aktiengesellschaft	Heterodimere mrp8/mrp14 ou ses composants individuels combines pour le traitement et/ou la prevention de maladies cutanees, de blessures et/ou de troubles de la cicatrisation des blessures caracterises par une quantite reduite d'heterodimeres mrp8/mrp14

2011
- 2011-06-21 NO NO20110896A patent/NO336551B1/no not_active IP Right Cessation
2012
- 2012-06-21 WO PCT/EP2012/061948 patent/WO2012175602A2/fr not_active Ceased

Also Published As

Publication number	Publication date
WO2012175602A2 (fr)	2012-12-27
WO2012175602A3 (fr)	2013-06-13
NO20110896A1 (no)	2012-12-24

Legal Events

Date	Code	Title	Description
2019-01-28	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
NO336551B1 (no)	2015-09-28	Forbedret ELISA for kalprotektin i fekalprøve eller gastrointestinaltraktsprøve
JP2010525362A (ja)	2010-07-22	免疫調節剤のスクリーニング方法
US12534523B2 (en)	2026-01-27	DNA-replication associated (Rep) protein antibody
NO20110895A1 (no)	2012-12-24	Kompetitive S100A9 immunoanalyser
US10907141B2 (en)	2021-02-02	Rep protein for use in a diagnostic assay
US8399207B2 (en)	2013-03-19	Monoclonal antibodies against osteopontin
WO2023061388A1 (fr)	2023-04-20	Dosage immunologique de galectine-3
US9915667B2 (en)	2018-03-13	Methods and means for diagnosing vasculitis
CN106537147A (zh)	2017-03-22	通过测定ast的含量诊断、预后或监测肝脏疾病的试剂盒和方法
CN104330570B (zh)	2016-03-16	人热休克蛋白gp96在制备筛查肝病的产品中的应用
US12601738B2 (en)	2026-04-14	Method and means for diagnosis of spondyloarthritis
JP2014162772A (ja)	2014-09-08	抗シトルリン化タンパクヒトＩｇＧ抗体およびその用途
WO2008012941A1 (fr)	2008-01-31	Méthode de diagnostic d'une insuffisance cardiaque
CA3039138C (fr)	2025-11-25	Proteine rep en tant qu'antigene proteique pour utilisation dans des dosages diagnostiques
JP2024070581A (ja)	2024-05-23	Ａｌｓ検査用バイオマーカー及び検査方法
WO2023191046A1 (fr)	2023-10-05	Procédé de mesure d'hrg faisant appel à des anticorps monoclonaux anti-hrg
JP2024022080A (ja)	2024-02-16	ポリペプチド、抗ｅ型肝炎ウイルス抗体の検出方法、抗ｅ型肝炎ウイルス抗体及びｅ型肝炎ウイルスの同時検出方法、及びキット
US20160223569A1 (en)	2016-08-04	Novel non-invasive methods of monitoring hiv viral loads
HK40016702A (en)	2020-09-11	Rep protein as protein antigen for use in diagnostic assays
JP2010285416A (ja)	2010-12-24	Ａｄｍ抗体エピトープペプチドおよびその利用